Tag: Eosinophilic granulomatosis with polyangiitis

Eosinophilic lung diseases are a diverse group of disorders characterized by the accumulation of eosinophils in the lung tissue. The specific diagnosis determines what is the medicine for eosinophilia in the lungs, with treatment approaches ranging from general anti-inflammatory drugs to highly targeted biologic therapies.

Approved by the FDA in 2017, benralizumab is a biologic medication designed for the add-on maintenance treatment of severe eosinophilic asthma. This article explains **what class of drug is benralizumab** and its unique mechanism of targeting the interleukin-5 (IL-5) receptor to reduce eosinophil-driven inflammation.